e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Cystic fibrosis: clinical problems and microbiology in adults
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
C. Green, A. Y. H. Lim (Stoke on Trent, United Kingdom; Singapore, Singapore)
Source:
Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Session:
Cystic fibrosis: clinical problems and microbiology in adults
Session type:
Thematic Poster Session
Number:
1170
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Green, A. Y. H. Lim (Stoke on Trent, United Kingdom; Singapore, Singapore). Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization. Eur Respir J 2013; 42: Suppl. 57, 1170
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Eosinophilic COPD
Related content which might interest you:
The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 156
Year: 2001
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Annual Congress 2009 - Update on eosinophilic lung diseases
Year: 2009
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 1052-1053
Year: 2001
Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis
Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020
Year: 2020
Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis
Source: Eur Respir J 2003 Oct 01;22(4):592-595
Year: 2003
Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Vitamin D deficiency in asthma patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013
Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis
Source: Eur Respir Rev 2010 19: 349-351
Year: 2010
Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2008; 31: 36-42
Year: 2008
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
A new risk factor predicts ABPA in patients with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015
Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2016; 47: 177-185
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept